REGISTER
FDA Grants Accelerated Approval to BeiGene's Sonrotoclax for Relapsed/Refractory Mantle
The U.S. FDA has granted accelerated approval to sonrotoclax (BCL2 inhibitor) for adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy, including a BTK inhibitor. This marks the first new BCL2 inhibitor approved in the U.S. in a decade and the only BCL2 inhibitor currently approved for MCL.

On May 14, BeiGene announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to sonrotoclax, a BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a BTK inhibitor.


This approval carries two notable distinctions. It is the first new BCL2 inhibitor to receive FDA approval in a decade. It is also the only BCL2 inhibitor currently approved for an MCL indication in the United States. Before this approval, patients with MCL who progressed after BTK inhibitor therapy faced a significant gap in targeted treatment options. Sonrotoclax addresses that unmet need directly.


The approval also reflects BeiGene's expanding global regulatory footprint. The company now has three FDA-approved products: sonrotoclax, zanubrutinib (a BTK inhibitor), and tislelizumab (a PD-1 monoclonal antibody). This multi-product track record strengthens BeiGene's credibility for future global clinical development and regulatory submissions.

0
0
Loading